A bioorthogonal-catalytic artificial antigen-presenting cell for chemo- and immuno-therapy

Résumé fourni par la source

catalytic prodrug activation and immunomodulation. Particularly, localized activation of a doxorubicin prodrug kills tumor cells and induces immunogenic cell death (ICD), thereby releasing tumor-associated antigens and priming personalized antitumor immunity. Concurrently, dendritic cell membrane-derived ligand-receptor interactions facilitate T cell activation and proliferation. This synergistic strategy enables efficient antigen presentation and robust immune activation. The presented approach offers a versatile paradigm for engineering catalytic aAPCs toward bioorthogonal cancer immunotherapy.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.